Gubra releases its results for the first quarter of 2025. The key development in the quarter was the out-licensing agreement to AbbVie for our anti-obesity asset GUBamy (Amylin). A landmark deal ...

Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second ...

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25 mg group compared with a 2.2% reduction in the placebo group.

Semaglutide is the key component of weight loss and diabetes drugs like Ozempic and Wegovy, and an international team of researchers has now discovered it can also do wonders for people who have ...

There are currently no drugs approved in the European Union to treat the liver condition known as MASH, but a new trial of ...

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by the common condition ...

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by a common condition.

The diabetes and weight loss drug semaglutide reversed liver scarring and inflammation. It’s among several drugs in the works for the condition MASH.

In recent years, glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide ... that this weight loss improves OSA symptoms. 1 The results that led to Zepbound’s approval for sleep apnea ...

Tracy Byers' experience with semaglutides began dramatically with her first dose, marking a significant turning point in her relationship with food. For the first time in her life, she would ...